JP2019506435A - ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 - Google Patents

ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 Download PDF

Info

Publication number
JP2019506435A
JP2019506435A JP2018544832A JP2018544832A JP2019506435A JP 2019506435 A JP2019506435 A JP 2019506435A JP 2018544832 A JP2018544832 A JP 2018544832A JP 2018544832 A JP2018544832 A JP 2018544832A JP 2019506435 A JP2019506435 A JP 2019506435A
Authority
JP
Japan
Prior art keywords
hpv
dose
vaccine
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018544832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506435A5 (enExample
Inventor
アイオナイデス ティム
アイオナイデス ティム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of JP2019506435A publication Critical patent/JP2019506435A/ja
Publication of JP2019506435A5 publication Critical patent/JP2019506435A5/ja
Priority to JP2021108667A priority Critical patent/JP7732784B2/ja
Priority to JP2023092142A priority patent/JP2023110038A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2018544832A 2016-02-27 2017-02-24 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 Pending JP2019506435A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021108667A JP7732784B2 (ja) 2016-02-27 2021-06-30 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
JP2023092142A JP2023110038A (ja) 2016-02-27 2023-06-05 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US62/300,785 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US62/328,487 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US62/338,183 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US62/444,576 2017-01-10
US201762455434P 2017-02-06 2017-02-06
US62/455,434 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021108667A Division JP7732784B2 (ja) 2016-02-27 2021-06-30 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2019506435A true JP2019506435A (ja) 2019-03-07
JP2019506435A5 JP2019506435A5 (enExample) 2020-04-02

Family

ID=59686556

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018544832A Pending JP2019506435A (ja) 2016-02-27 2017-02-24 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
JP2021108667A Active JP7732784B2 (ja) 2016-02-27 2021-06-30 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
JP2023092142A Pending JP2023110038A (ja) 2016-02-27 2023-06-05 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021108667A Active JP7732784B2 (ja) 2016-02-27 2021-06-30 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
JP2023092142A Pending JP2023110038A (ja) 2016-02-27 2023-06-05 ワクチンを使用して癌または皮膚病変を治療するための方法および組成物

Country Status (16)

Country Link
EP (1) EP3419661A4 (enExample)
JP (3) JP2019506435A (enExample)
KR (1) KR102873848B1 (enExample)
CN (1) CN108883168A (enExample)
AU (1) AU2017223970B2 (enExample)
BR (1) BR112018067550A2 (enExample)
CA (1) CA3015519A1 (enExample)
CL (1) CL2018002438A1 (enExample)
CO (1) CO2018009205A2 (enExample)
HK (1) HK1256935A1 (enExample)
IL (1) IL261340B2 (enExample)
MX (1) MX2018010338A (enExample)
MY (1) MY194694A (enExample)
SG (1) SG11201807080UA (enExample)
WO (1) WO2017147475A1 (enExample)
ZA (1) ZA201805679B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546073A (ja) * 2020-10-12 2023-11-01 エイチピーブイヴァックス，リミテッド ライアビリティー カンパニー． 第１の治療有効成分としてのワクチンを、第２の有効成分と組み合わせて使用する、癌を治療するための組成物及び方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (zh) * 2019-07-19 2024-04-09 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
CN120302980A (zh) * 2022-10-31 2025-07-11 皮洛杰斯股份有限公司 免疫疗法组合物和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514696A (ja) * 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
WO2015106281A1 (en) * 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
JP6663438B2 (ja) * 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP2419143B8 (en) * 2009-04-13 2018-06-27 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
AU2010264695A1 (en) * 2009-06-25 2012-01-19 Glaxosmithkline Biologicals S.A. Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
WO2012170384A1 (en) * 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20160062759A (ko) * 2013-10-13 2016-06-02 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 인간 유두종 바이러스 치료 백신

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514696A (ja) * 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
WO2015106281A1 (en) * 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
JP6663438B2 (ja) * 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546073A (ja) * 2020-10-12 2023-11-01 エイチピーブイヴァックス，リミテッド ライアビリティー カンパニー． 第１の治療有効成分としてのワクチンを、第２の有効成分と組み合わせて使用する、癌を治療するための組成物及び方法

Also Published As

Publication number Publication date
AU2017223970B2 (en) 2022-01-27
AU2017223970A1 (en) 2018-09-13
KR102873848B1 (ko) 2025-10-17
EP3419661A4 (en) 2019-10-23
CO2018009205A2 (es) 2018-09-20
KR20180112043A (ko) 2018-10-11
MY194694A (en) 2022-12-15
WO2017147475A1 (en) 2017-08-31
HK1256935A1 (zh) 2019-10-04
IL261340A (en) 2018-11-29
IL261340B1 (en) 2023-03-01
BR112018067550A2 (pt) 2019-10-01
EP3419661A1 (en) 2019-01-02
IL261340B2 (en) 2023-07-01
JP2021155448A (ja) 2021-10-07
MX2018010338A (es) 2018-11-09
JP7732784B2 (ja) 2025-09-02
CN108883168A (zh) 2018-11-23
ZA201805679B (en) 2019-11-27
CA3015519A1 (en) 2017-08-31
SG11201807080UA (en) 2018-09-27
JP2023110038A (ja) 2023-08-08
CL2018002438A1 (es) 2019-01-04

Similar Documents

Publication Publication Date Title
US11389472B2 (en) Method of administration and treatment
JP2023110038A (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
JP2024164177A (ja) 疣贅の治療
JP2023126760A (ja) 抗炎症剤
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
TW202502805A (zh) 新多功能寡肽
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
ES3002532T3 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
US10485823B2 (en) Method for treating cervical intraepithelial neoplasia using poly-gamma- glutamic acid
CN107308145B (zh) 苯乙双胍在制备抗皮肤炎症制剂中的用途
HK40055016A (en) Treatment of warts
WO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬
EP3241555A1 (en) Use of pyrophosphate ion analogues for the treatment of hpv infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211019